Boehringer Ingelheim International GmbH

Boehringer Ingelheim is a global, research-driven pharmaceutical company headquartered in Ingelheim am Rhein, Germany. Founded in 1885, its core mission is to improve the health and quality of life for both humans and animals by discovering, developing, manufacturing, and marketing innovative healthcare products. The company operates as a private entity, fully owned by the Boehringer, Liebrecht, and von Baumbach families, which allows for a long-term, sustainable strategic focus.

The company's operations are divided into Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In Human Pharma, Boehringer Ingelheim focuses on therapeutic areas such as respiratory diseases, metabolism, immunology, oncology, cardiovascular, central nervous system disorders, and retinal health. Key products include Jardiance for type 2 diabetes, heart failure, and chronic kidney disease; Ofev for pulmonary fibrosis; Spiriva for COPD; and Pradaxa as an anticoagulant. Its Animal Health business provides vaccines, parasiticides, and pharmaceuticals for pets, horses, swine, ruminants, and poultry, with brands like NexGard and Frontline.

Boehringer Ingelheim is recognized as one of the world's largest pharmaceutical companies and the largest private one, employing approximately 54,300 people across 130 markets globally. Recent developments include promising Phase 3 results for its obesity drug candidate, survodutide, and the launch of an AI-based solution for detecting heart murmurs in dogs in partnership with Eko Health Inc.. The company also received FDA approval for JASCAYD® (nerandomilast) for progressive pulmonary fibrosis and a targeted therapy for HER2-mutant advanced non-small cell lung cancer in late 2025 and early 2026, respectively.